title: MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy.
authors.forename: Kalman
authors.initials: K
authors.lastname: Kovacs
authors.forename: Bernd W
authors.initials: BW
authors.lastname: Scheithauer
authors.forename: Matilde
authors.initials: M
authors.lastname: Lombardero
authors.forename: Roger E
authors.initials: RE
authors.lastname: McLendon
authors.forename: Luis V
authors.initials: LV
authors.lastname: Syro
authors.forename: Humberto
authors.initials: H
authors.lastname: Uribe
authors.forename: Leon D
authors.initials: LD
authors.lastname: Ortiz
authors.forename: Luis C
authors.initials: LC
authors.lastname: Penagos
mesh_terms: D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D015254:DNA Modification Methylases / Q000096:biosynthesis*; D045643:DNA Repair Enzymes / Q000096:biosynthesis*; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D019008:Drug Resistance, Neoplasm / Q000502:physiology*; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D010911:Pituitary Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D000077204:Temozolomide; D025521:Tumor Suppressor Proteins / Q000096:biosynthesis*
chemical_list: D018906:Antineoplastic Agents, Alkylating; D025521:Tumor Suppressor Proteins; D003606:Dacarbazine; D015254:DNA Modification Methylases; C515491:MGMT protein, human; D045643:DNA Repair Enzymes; D000077204:Temozolomide